Loading cancer entity…
Loading cancer entity…
Clinical trials
8 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07805798 | Urinary Bladder Matrix (UBM) Registry | not yet recruiting | — | 300 | Integra LifeSciences CorporationINDUSTRY | 0 | Sep 4, 2026 | clinicaltrials |
| NCT07301424 | Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL | not yet recruiting | Phase 2 | 80 | University of AlbertaOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07428941 | Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.(LegitHealth PH) | completed | — | 9 | AI Labs Group S.LINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07152041 | Newly-diagnosed Pediatric Ph-positive B-ALL Protocol |
Data updated 22 days agoSource updated Sep 4, 2026source: clinicaltrials
| recruiting |
| Phase 3 |
| 150 |
| Institute of Hematology & Blood Diseases Hospital, ChinaOTHER |
| 2 |
| Sep 3, 2025 |
| clinicaltrials |
| NCT07021495 | SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)(SKINERGY) | recruiting | — | 840 | Leiden University Medical CenterOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT01131325 | Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations(MACS1148) | terminated | Phase 4 | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | May 20, 2021 | clinicaltrials |
| NCT01221376 | Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+) | unknown | Phase 2 | 20 | Renato MelaragnoOTHER | 1 | Mar 26, 2013 | clinicaltrials |
| NCT01222013 | Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) | suspended | Phase 2 | 20 | Renato MelaragnoOTHER | 0 | Mar 26, 2013 | clinicaltrials |